Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Norway Loophole

This article was originally published in Start Up

Executive Summary

Cambridge Antibody Technology has built a business based on an exclusive license to a key biotech patent on antibody expression libraries. But the patent holder, Medical Research Council, neglected to file for a patent in Norway. Enter Affitech, which has taken advantage of the loophole to obtain a patent on a more efficient way of creating and screening phage-derived antibody libraries and in the process creating new competition for CAT. Although Affitech can't sell the antibodies it screens outside of Norway, it claims it can legally sell optimized, already screened antibodies to anyone who wants them. And it believes it has an eager customer base.

Related Content

Leveraging Antibodies
Engineering Protein Pharmaceuticals


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts